A peptoid "Antibody surrogate" that antagonizes VEGF receptor 2 activity

Division of Translational Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9185, USA.
Journal of the American Chemical Society (Impact Factor: 11.44). 05/2008; 130(17):5744-52. DOI: 10.1021/ja711193x
Source: PubMed

ABSTRACT We report a two-color, cell-based screen to identify specific receptor-binding compounds in a combinatorial library of peptoids displayed on beads. We apply this strategy to the isolation of vascular endothelial growth factor receptor 2 (VEGFR2)-binding peptoids. A dimeric derivative of one of these lead compounds is shown to be an antagonist of VEGFR2 activity both in vitro and in vivo. This methodology provides a potentially general route to synthetic molecules that bind integral membrane receptors with affinities and specificities similar to those of antibodies, but which are far smaller and easier to make and manipulate.


Available from: Gomika Udugamasooriya, May 30, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases, represent an important target class for treating human disorders. This review focus on "the 10 things you should know about protein kinases and their inhibitors" including a short introduction on the history on protein kinases and inhibitor and ending with a perspective in kinase drug discovery. Although the "10 things" have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the "status quo" of the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs this review also focus on their limitations, in particular on how to circumvent emerging resistance against kinase inhibitors in oncological indications. This article is protected by copyright. All rights reserved.
    British Journal of Pharmacology 01/2015; 172(11). DOI:10.1111/bph.13096 · 4.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Poly(N-substituted glycine) “peptoids” have conventionally been exploited for drug discovery and therapeutics due to their structural similarity to peptides, protease resistance, and relative ease of synthesis. This mini-review highlights recent reports of peptoid self-assembled nanostructures and macromolecular interfaces relevant to biomaterials science. The results illustrate how the versatility of peptoid design and synthesis could be exploited to generate multifunctional, modular and precisely tunable biointerfaces and biomaterials.
    01/2014; 2(5):627. DOI:10.1039/c3bm60269a
  • [Show abstract] [Hide abstract]
    ABSTRACT: Deregulation of protein and lipid kinases of these kinase activities lead to a variety of pathologies ranging from cancer to inflammatory diseases, diabetes, infectious diseases, cardiovascular disorders, cell growth and survival. Protein kinase and lipid kinases represent, therefore, an important target for the pharmaceutical industry. In fact, approximately one third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases. To date 27 kinase inhibitors that have been approved, which, with few exceptions, are mainly for oncological indications and are directed against only a handful of protein and lipid kinases, leaving 70% of the kinome untapped. Despite of these successes the major challenges in kinase drug discovery the development of kinase inhibitors with outstanding selectivity, the identification and validation of driver kinase(s) in diseases and the emerging resistance to the inhibition of key target kinases remain major challenges. This review will provide an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors and novel avenues for the generation of second generation kinase inhibitors to treat cancers. The American Society for Pharmacology and Experimental Therapeutics.
    Molecular pharmacology 12/2014; DOI:10.1124/mol.114.095489 · 4.12 Impact Factor